Adze-1.17-CD40L / Adze Biotech - LARVOL DELTA

Adze Biotechnology Announces Orphan Drug Designation Granted to Adze-1.17-CD40L for the treatment of Malignant Glioma (EIN Presswire) - "Adze Biotechnology, Inc....announced today that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for Adze-1.17-CD40L, for treatment of Malignant Glioma. Adze-1.17-CD40L is a systemically deliverable, conditionally replicative oncolytic virus that delivers a recombinent human CD40 ligand locally into solid tumors....Adze plans to begin clinical trials in 2024 in melanoma in using Adze systemically deliverable oncolytic immunotherapies. Additionally, clinical trials in prostate cancer are being planned for 2025."

Orphan drug • Brain Cancer • CNS Tumor • Genito-urinary Cancer • Glioma • Melanoma • Oncology • Prostate Cancer • Skin Cancer • Solid Tumor